These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 20206069)

  • 21. Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio.
    Worasuwannarak S; Pornratanarangsi S
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S29-34. PubMed ID: 20364554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention.
    Seyon RA; Jensen LA; Ferguson IA; Williams RG
    Heart Lung; 2007; 36(3):195-204. PubMed ID: 17509426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty.
    Aslanger E; Uslu B; Akdeniz C; Polat N; Cizgici Y; Oflaz H
    Coron Artery Dis; 2012 Jun; 23(4):265-70. PubMed ID: 22343798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of hydration with or without n-acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention.
    Awal A; Ahsan SA; Siddique MA; Banerjee S; Hasan MI; Zaman SM; Arzu J; Subedi B
    Mymensingh Med J; 2011 Apr; 20(2):264-9. PubMed ID: 21522098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
    Habib M; Hillis A; Hammad A
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy--a randomized controlled study.
    Ferrario F; Barone MT; Landoni G; Genderini A; Heidemperger M; Trezzi M; Piccaluga E; Danna P; Scorza D
    Nephrol Dial Transplant; 2009 Oct; 24(10):3103-7. PubMed ID: 19549691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of n-acetylcysteine in preventing contrast-induced nephropathy in type 2 diabetic patients without nephropathy.
    Sar F; Saler T; Ecebay A; Saglam ZA; Ozturk S; Kazancioglu R
    J Nephrol; 2010; 23(4):478-82. PubMed ID: 20383874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of anisodamine on prevention of contrast induced nephropathy in patients with acute coronary syndrome.
    Wang YB; Fu XH; Gu XS; Wang XC; Zhao YJ; Hao GZ; Jiang YF; Fan WZ; Wu WL; Li SQ; Xue L
    Chin Med J (Engl); 2012 Mar; 125(6):1063-7. PubMed ID: 22613532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration.
    Marenzi G; Marana I; Lauri G; Assanelli E; Grazi M; Campodonico J; Trabattoni D; Fabbiocchi F; Montorsi P; Bartorelli AL
    N Engl J Med; 2003 Oct; 349(14):1333-40. PubMed ID: 14523141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of acute renal failure post-contrast imaging in cardiology: a randomized study.
    Alessandri N; Lanzi L; Garante CM; Tersigni F; Sergiacomi R; Petrassi M; Di Matteo A; Tufano F
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17 Suppl 1():13-21. PubMed ID: 23436661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cystatin C and creatinine as markers for radiocontrast-induced nephropathy in patients treated with N-acetylcysteine.
    Merkle M; Sauter M; Argirov M; Wörnle M
    Ren Fail; 2010 Jan; 32(1):85-90. PubMed ID: 20113272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study.
    Recio-Mayoral A; Chaparro M; Prado B; Cózar R; Méndez I; Banerjee D; Kaski JC; Cubero J; Cruz JM
    J Am Coll Cardiol; 2007 Mar; 49(12):1283-8. PubMed ID: 17394959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN).
    Ng TM; Shurmur SW; Silver M; Nissen LR; O'Leary EL; Rigmaiden RS; Cieciorka M; Porter LL; Ineck BA; Kline ME; Puumala SE
    Int J Cardiol; 2006 May; 109(3):322-8. PubMed ID: 16039733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis.
    Duong MH; MacKenzie TA; Malenka DJ
    Catheter Cardiovasc Interv; 2005 Apr; 64(4):471-9. PubMed ID: 15789388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contrast nephropathy in high-risk patients undergoing coronary angiography and intervention.
    Uddin MA; Rabbani MA; Jafary FH; Bhatti MA; Islam M
    J Coll Physicians Surg Pak; 2005 Dec; 15(12):791-4. PubMed ID: 16398973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials.
    Zagler A; Azadpour M; Mercado C; Hennekens CH
    Am Heart J; 2006 Jan; 151(1):140-5. PubMed ID: 16368307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome.
    Senoo T; Motohiro M; Kamihata H; Yamamoto S; Isono T; Manabe K; Sakuma T; Yoshida S; Sutani Y; Iwasaka T
    Am J Cardiol; 2010 Mar; 105(5):624-8. PubMed ID: 20185007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature.
    Goldenberg I; Shechter M; Matetzky S; Jonas M; Adam M; Pres H; Elian D; Agranat O; Schwammenthal E; Guetta V
    Eur Heart J; 2004 Feb; 25(3):212-8. PubMed ID: 14972421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Xinwei J; Xianghua F; Jing Z; Xinshun G; Ling X; Weize F; Guozhen H; Yunfa J; Weili W; Shiqiang L
    Am J Cardiol; 2009 Aug; 104(4):519-24. PubMed ID: 19660605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial.
    Thayssen P; Lassen JF; Jensen SE; Hansen KN; Hansen HS; Christiansen EH; Junker A; Ravkilde J; Thuesen L; Veien KT; Jensen LO
    Circ Cardiovasc Interv; 2014 Apr; 7(2):216-24. PubMed ID: 24714489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.